Overview

• Vir Biotechnology Q3 revenue missed analyst expectations, declining significantly year-over-year

• Net loss for Q3 decreased to $163.1 mln from $213.7 mln year-over-year

• Company maintains strong cash position with $810.7 mln, funding operations into mid-2027

Outlook

• Company expects cash reserves to fund operations into mid-2027

• Topline data for ECLIPSE trials expected in Q1 2027

Result Drivers

• R&D expenses for the third quarter of 2025 were $151.5 million, compared to $195.2 million for the same period in 2024

• ONCOLOGY EXPANSION - First patient dosed in Phase 1 study of VIR-5500 in combination with ARPIs for prostate cancer

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Vir Biotechnology Inc is $15.00, about 65% above its November 4 closing price of $5.25

Press Release: ID:nBwYcK9Qa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)